Read + Share
Rahma OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for
Immune Checkpoint Inhibitors. Clin Cancer Res 2021;27:485-491.
PMID: 33082209
|
 |
|
Rahma OE, Reuss JE, Giobbie-Hurder A, Shoja E Razavi G, et al. Early 3+3 Trial Dose-Escalation Phase I Clinical Trial Design and Suitability for
Immune Checkpoint Inhibitors. Clin Cancer Res 2021;27:485-491.
PMID: 33082209
|
|
|
|